- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07300995
Behavioral Pain Intervention for Older Cancer Patients
June 1, 2026 updated by: Duke University
Brief Pain Coping Skills Training for Older Women With Breast Cancer and Pain: An Efficacy-Effectiveness Randomized Controlled Trial
This randomized controlled trial examines a 1-session, telehealth pain coping skills training (PCST) protocol with five 15-minute maintenance calls (Brief PCST-Community) adapted for women with breast cancer in medically underserved areas.
Pain, health-related quality of life, and self-efficacy for pain management will be assessed at baseline and 10 and 15 weeks later.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Pain continues to be persistent, interfering, and distressing for women with breast cancer.
Behavioral cancer pain interventions continue to be poorly implemented with pronounced disparities for older breast cancer patients receiving oncology care in medically underserved areas.
Within this context, this randomized controlled trial examines a 1-session, telehealth pain coping skills training (PCST) protocol with five 15-minute maintenance calls (Brief PCST-Community) adapted for women with breast cancer in medically underserved areas.
Pain, health-related quality of life, and self-efficacy for pain management will be assessed at baseline and 10 and 15 weeks later.
Study Type
Interventional
Enrollment (Estimated)
168
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tamara Somers, PhD
- Phone Number: 919-416-3408
- Email: tamara.somers@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27713
- Recruiting
- Duke Cancer Network
-
Contact:
- Tamara Somers
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Receiving cancer care at a Duke Cancer Network (DCN) clinic
- Stage I-IV breast cancer
- Self-reported pain on at least 10 days in the last month and pain rating of worst pain of 4 or greater on a 0-10 scale in the last week
- Biologically female
- Greater than or equal to 55 years old
- Ability to speak and read English
- Hearing and vision that allows for successful completion of videoconferencing and phone session
Exclusion Criteria:
- Participation in the last 6 months in a pain coping skills training program
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pain Coping Skills Training
Participants in this group will complete a 50-minute telehealth session with a trained study nurse.
During this session, they will be taught how to use several coping strategies for managing pain.
This will be followed by 5 weekly, 15-minute supportive phone calls, where the study nurse will reinforce the learned coping skills.
They will be asked to complete 2 follow-up surveys (10 weeks and 15 weeks after the first survey).
|
Behavioral pain intervention delivered via telehealth.
|
|
No Intervention: Usual Care
Participants in this group will not complete the new program.
They will be asked to complete 2 follow-up surveys (10 and 15 weeks after the first survey).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain severity as measured by the Brief Pain Inventory (BPI)
Time Frame: Baseline, 10-week assessment, 15-week assessment
|
BPI Pain Severity (worst, least, average, current pain on 0-10 scale) scores are averaged for a total score range of 0 to 10, with higher scores indicating greater pain severity.
|
Baseline, 10-week assessment, 15-week assessment
|
|
Pain interference as measured by the Brief Pain Inventory (BPI)
Time Frame: Baseline, 10-week assessment, 15-week assessment
|
BPI Pain Interference (7 daily life areas such as mood, sleep, activity rated 0-10) scores are averaged for a total score range of 0 to 10, with higher scores indicating greater pain interference.
|
Baseline, 10-week assessment, 15-week assessment
|
|
Health Related Quality of Life (HR-QOL) as measured by the Patient Reported Outcomes Measurement Information System (PROMIS-29) - Physical Function
Time Frame: Baseline, 10-week assessment, 15-week assessment
|
A PROMIS Physical Function T-score is a standardized number (mean 50, SD 10) from the Patient-Reported Outcomes Measurement Information System (PROMIS) that reflects self-reported physical ability with higher scores indicating better function.
|
Baseline, 10-week assessment, 15-week assessment
|
|
Health Related Quality of Life (HR-QOL) as measured by the Patient Reported Outcomes Measurement Information System (PROMIS-29) - Mental Health
Time Frame: Baseline, 10-week assessment, 15-week assessment
|
A PROMIS Mental Health T-score is a standardized number (mean 50, SD 10) from the Patient-Reported Outcomes Measurement Information System (PROMIS) that reflects self-reported mental health with higher scores indicating worse mental health.
|
Baseline, 10-week assessment, 15-week assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-Efficacy for Pain Management
Time Frame: Baseline, 10-week assessment, 15-week assessment
|
The Pain Self-Efficacy Questionnaire (PSEQ) is a 10-item scale rating confidence (0-6) in specific tasks despite pain.
The total score ranges from 0 to 60, where higher scores indicate greater self-efficacy.
|
Baseline, 10-week assessment, 15-week assessment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 30, 2026
Primary Completion (Estimated)
April 30, 2027
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
December 22, 2025
First Submitted That Met QC Criteria
December 22, 2025
First Posted (Actual)
December 24, 2025
Study Record Updates
Last Update Posted (Actual)
June 2, 2026
Last Update Submitted That Met QC Criteria
June 1, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00117948
- P30AG022845 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Pain Coping Skills Training (PCST)
-
Wake Forest University Health SciencesHonorHealth Research InstituteWithdrawnCIPN - Chemotherapy-Induced Peripheral NeuropathyUnited States
-
Duke UniversityNational Institutes of Health (NIH); National Institute on Aging (NIA)Recruiting
-
University of Wisconsin, MadisonMedical College of Wisconsin; Wisconsin Partnership ProgramRecruitingTrauma Injury | Opioid MisuseUnited States
-
Duke UniversityCompletedPCST-Full (Pain Coping Skills Training) | PCST-BriefUnited States
-
Duke UniversityCompletedMobile Pain Coping Skills Training | In Person Pain Coping Skills TrainingUnited States
-
University of North Carolina, Chapel HillPatient-Centered Outcomes Research InstituteCompletedOsteoarthritisUnited States
-
Duke UniversityAmerican Cancer Society, Inc.CompletedPain | Advanced Solid TumorUnited States
-
Duke UniversityIcahn School of Medicine at Mount SinaiCompleted
-
Duke UniversityCompletedBreast CancerUnited States